![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Cipla Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Pramipexole dihydrochloride monohydrate, supported by a 'Valid' Certificate of Suitability (CEP) with the number CEP 2011-047 - Rev 03
This Chemical Type CEP, issued on July 05, 2024, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2416 associated with this CEP further emphasizes